MCID: NTR004
MIFTS: 61

Neutropenia

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Neutropenia

MalaCards integrated aliases for Neutropenia:

Name: Neutropenia 39 12 30 56 6 45 15 74 3
Leukopenia 74

Classifications:



External Ids:

Disease Ontology 12 DOID:1227
ICD9CM 36 288.0 288.00
MeSH 45 D009503
SNOMED-CT 69 72885007
ICD10 34 D70 D70.9

Summaries for Neutropenia

CDC : 3 Learn how chemotherapy raises your risk of getting an infection and what to do if you get an infection during chemotherapy.

MalaCards based summary : Neutropenia, also known as leukopenia, is related to cyclic neutropenia and severe congenital neutropenia autosomal dominant. An important gene associated with Neutropenia is VPS13B (Vacuolar Protein Sorting 13 Homolog B), and among its related pathways/superpathways are JAK-STAT signaling pathway (KEGG) and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Gemcitabine and Cytarabine have been mentioned in the context of this disorder. Affiliated tissues include breast, lung and myeloid, and related phenotypes are no effect and hematopoietic system

Wikipedia : 77 Neutropenia is an abnormally low concentration of neutrophils (a type of white blood cell) in the blood.... more...

Related Diseases for Neutropenia

Diseases in the Neutropenia family:

Neutropenia, Chronic Familial Neutropenia, Severe Congenital, 1, Autosomal Dominant
Neutropenia, Severe Congenital, 3, Autosomal Recessive Neutropenia, Severe Congenital, 4, Autosomal Recessive
Neutropenia, Severe Congenital, 2, Autosomal Dominant Neutropenia, Severe Congenital, 5, Autosomal Recessive
Neutropenia, Severe Congenital, 6, Autosomal Recessive Neutropenia, Severe Congenital, 7, Autosomal Recessive
Severe Congenital Neutropenia Elane-Related Neutropenia
Severe Congenital Neutropenia Autosomal Dominant

Diseases related to Neutropenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 502)
# Related Disease Score Top Affiliating Genes
1 cyclic neutropenia 34.1 CSF2 CSF3 ELANE G6PC3 IL3
2 severe congenital neutropenia autosomal dominant 34.0 ELANE GFI1
3 felty syndrome 33.2 CSF2 CSF3 IL3
4 severe congenital neutropenia 33.1 CSF2 CSF3 CSF3R ELANE G6PC3 GFI1
5 granulocytopenia 30.8 CSF2 CSF3 IL3
6 leukemia, acute myeloid 30.6 CSF2 CSF3 CSF3R GFI1 IL3
7 bacterial infectious disease 30.4 CSF2 CSF3 ELANE
8 aplastic anemia 30.2 CSF2 CSF3 CSF3R IL3
9 dyskeratosis congenita 30.0 CSF2 CSF3 USB1
10 myelodysplastic syndrome 30.0 CSF2 CSF3 CSF3R IL3 TOP1
11 acute promyelocytic leukemia 29.8 CSF3 CSF3R ELANE IL3
12 acute lymphocytic leukemia 29.8 CSF2 CSF3 TPMT
13 chronic neutrophilic leukemia 29.7 CSF3 CSF3R
14 leukemia, chronic myeloid 29.6 CD177 CSF2 CSF3 CSF3R IL3
15 chronic myelomonocytic leukemia 29.5 CSF2 CSF3R TOP1
16 pancytopenia 29.5 CSF2 CSF3 IL3 TPMT
17 hematologic cancer 29.2 CSF2 CSF3 CSF3R IL3 TOP1
18 poikiloderma with neutropenia 12.7
19 neutropenia, severe congenital, 3, autosomal recessive 12.6
20 neutropenia, nonimmune chronic idiopathic, of adults 12.5
21 neutropenia, severe congenital, x-linked 12.5
22 idiopathic neutropenia 12.5
23 3-methylglutaconic aciduria with cataracts, neurologic involvement, and neutropenia 12.4
24 neutropenia, severe congenital, 5, autosomal recessive 12.4
25 neutropenia, severe congenital, 7, autosomal recessive 12.4
26 neutropenia, severe congenital, 4, autosomal recessive 12.3
27 neutropenia, severe congenital, 1, autosomal dominant 12.3
28 neutropenia, severe congenital, 2, autosomal dominant 12.3
29 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 12.3
30 neutropenia, severe congenital, 6, autosomal recessive 12.3
31 neonatal alloimmune neutropenia 12.3
32 neutropenia, chronic familial 12.2
33 transient neonatal neutropenia 12.2
34 neutropenia, lethal congenital, with eosinophilia 12.2
35 barth syndrome 12.1
36 elane-related neutropenia 12.1
37 onychotrichodysplasia and neutropenia 12.0
38 neutropenia monocytopenia deafness 12.0
39 autosomal recessive severe congenital neutropenia due to cxcr2 deficiency 11.9
40 immunodeficiency 55 11.7
41 hermansky-pudlak syndrome 2 11.7
42 clpb deficiency 11.6
43 whim syndrome 11.6
44 leukemia, acute lymphoblastic 11.4
45 glycogen storage disease ib 11.4
46 wiskott-aldrich syndrome 11.4
47 large granular lymphocyte leukemia 11.3
48 immunodeficiency with hyper-igm, type 1 11.3
49 shwachman-diamond syndrome 1 11.3
50 cohen syndrome 11.2

Comorbidity relations with Neutropenia via Phenotypic Disease Network (PDN): (show all 46)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Acute Leukemia Agammaglobulinemia, X-Linked
Anemia, Autoimmune Hemolytic Bladder Cancer
Bronchitis Chronic Kidney Failure
Colorectal Cancer Decubitus Ulcer
Deficiency Anemia Esophageal Cancer
Esophageal Candidiasis Esophagitis
Felty Syndrome Female Breast Cancer
Gastric Cancer Heart Disease
Hepatic Encephalopathy Hydronephrosis
Hypersplenism Hypothyroidism
Immune Deficiency Disease Immunodeficiency-Centromeric Instability-Facial Anomalies Syndrome 1
Intestinal Obstruction Iron Deficiency Anemia
Leukemia, Chronic Lymphocytic Main Bronchus Cancer
Megakaryocytic Leukemia Oral Candidiasis
Ovarian Cancer Paralytic Ileus
Pneumocystosis Portal Hypertension
Postinflammatory Pulmonary Fibrosis Primary Thrombocytopenia
Protein-Energy Malnutrition Pulmonary Fibrosis and/or Bone Marrow Failure, Telomere-Related, 2
Respiratory Failure Retinitis Pigmentosa and Erythrocytic Microcytosis
Rheumatoid Arthritis Sideroblastic Anemia
Systemic Lupus Erythematosus Waldenstrom Macroglobulinemia

Graphical network of the top 20 diseases related to Neutropenia:



Diseases related to Neutropenia

Symptoms & Phenotypes for Neutropenia

GenomeRNAi Phenotypes related to Neutropenia according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 CD177 CLPB CSF2 CSF3 CSF3R ELANE

MGI Mouse Phenotypes related to Neutropenia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.73 CD177 CSF2 CSF3 CSF3R ELANE G6PC3
2 immune system MP:0005387 9.36 CD177 CSF2 CSF3 CSF3R ELANE G6PC3

Drugs & Therapeutics for Neutropenia

Drugs for Neutropenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 737)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 4,Phase 2,Phase 3,Phase 1 95058-81-4 60750
2
Cytarabine Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147-94-4, 65-46-3 6253
3
Doxorubicin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 23214-92-8 31703
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 1177-87-3
5
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 6857599 5310940 9887054 43805
6
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
7
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1 33419-42-0 36462
8
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
9
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
10
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 441203 84093 2767
11
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
12
Epirubicin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 56420-45-2 41867
13
Methotrexate Approved Phase 4,Phase 2,Phase 3,Phase 1 1959-05-2, 59-05-2 126941
14
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
15
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 124-94-7 31307
16
Tazobactam Approved Phase 4,Phase 2,Not Applicable 89786-04-9 123630
17
Vancomycin Approved Phase 4,Phase 3,Phase 2,Not Applicable 1404-90-6 441141 14969
18
Piperacillin Approved Phase 4,Phase 2,Not Applicable 66258-76-2 43672
19
Meropenem Approved, Investigational Phase 4,Phase 2 119478-56-7, 96036-03-2 441130 64778
20
Ceftazidime Approved Phase 4,Phase 3,Phase 2 78439-06-2, 72558-82-8 5481173
21
Micafungin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 235114-32-6 477468 3081921
22
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
23
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 85721-33-1 2764
24
Trimethoprim Approved, Vet_approved Phase 4,Phase 2 738-70-5 5578
25
Sulfamethoxazole Approved Phase 4,Phase 2 723-46-6 5329
26
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
27
Sargramostim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 123774-72-1, 83869-56-1
28
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
29
leucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-05-9 6006 143
30
Voriconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 137234-62-9 71616
31
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 38904 10339178 498142
32
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-24-8 5755
33
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 83-43-2 6741
34
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 302-25-0
35
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Phase 1 2921-57-5
36
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1 51-21-8 3385
37
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
38
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 58957-92-9 42890
39
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 154361-50-9 60953
40
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
41
Everolimus Approved Phase 4,Phase 2,Phase 1 159351-69-6 6442177 70789204
42
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
43
Valganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 175865-60-8 64147
44
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 82410-32-0 3454
45
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1 174722-31-7 10201696
46
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 150399-23-8, 137281-23-3 60843 446556
47
Lenalidomide Approved Phase 4,Phase 1,Phase 2 191732-72-6 216326
48
Ofloxacin Approved Phase 4,Phase 3,Not Applicable 82419-36-1 4583
49
Levofloxacin Approved, Investigational Phase 4,Phase 3,Not Applicable 100986-85-4 149096
50
Imipenem Approved Phase 4,Phase 2,Phase 3,Not Applicable 74431-23-5, 64221-86-9 104838

Interventional clinical trials:

(show top 50) (show all 1505)
# Name Status NCT ID Phase Drugs
1 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
2 Prevention of Neutropenia After Using G-CSF With TAC Chemotherapy Unknown status NCT01571518 Phase 4 late leukostim;early leukostim
3 Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia Unknown status NCT02463747 Phase 4 Piperacillin/tazobactam;Ceftazidim;Meropenem;Vancomycin
4 Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer Unknown status NCT00030758 Phase 4
5 The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy Unknown status NCT02905916 Phase 4 PEG-rhG-CSF
6 Micafungin Prevention Study for Fungal Disease in Child Receiving Allogenic Hematopoietic Stem Cell Transplantation Unknown status NCT01135589 Phase 4 Micafungin
7 Blood Draw Validation for Ciprofloxacin Pharmacokinetic Research in Pediatric Cancer Patients Unknown status NCT02967341 Phase 4
8 Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients Unknown status NCT02605213 Phase 4 Vancomycin;Placebo
9 Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda Unknown status NCT00674921 Phase 4 cotrimoxazole;Placebo
10 THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS Unknown status NCT02241876 Phase 4 N-acetylcysteine
11 Study to Reduce Duration of Antibiotic Therapy in Haematological Patients With Fever and Neutropenia Completed NCT01581333 Phase 4 Empirical antimicrobial treatment discontinuation;Standard empirical antimicrobial treatment discontinuation
12 Comparison of the Pharmacodynamics of Imipenem in Patients With Febrile Neutropenia Completed NCT02213783 Phase 4 Imipenem;Imipenem
13 PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent Neutropenia Completed NCT02805205 Phase 4 PEG-rhG-CSF
14 A Clinical Trial of Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Docetaxel Based Regimen Completed NCT01107756 Phase 4 LENOGRASTIM (GRANOGYTE 34)
15 Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer Completed NCT01649635 Phase 4 CABAZITAXEL (XRP6258);Prednisone;Ciprofloxacin;G-CSF (Granulocyte colony-stimulating factor)
16 REaCT Integrated Consent Model to Compare Two Standard of Care Regimens Completed NCT02173262 Phase 4 G-CSF;Ciprofloxacin
17 Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
18 Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients Completed NCT01401010 Phase 4 Doripenem;doripenem
19 PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy Completed NCT02805153 Phase 4 PEG-rhG-CSF;rhG-CSF
20 Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy Completed NCT00115206 Phase 4 Neulasta® (pegfilgrastim)
21 A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4 Neulasta (pegfilgrastim)
22 FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy Completed NCT00125723 Phase 4
23 Comparison of Teicoplanin and Vancomycin in Initial Empirical Antibiotic Regimen for Febrile Neutropenic Patients Completed NCT00454272 Phase 4 Teicoplanin;Vancomycin
24 Safety of Cotrimoxazole in HIV- and HAART-exposed Infants Completed NCT01086878 Phase 4 cotrimoxazole
25 Diagnosis of Septicaemia by Detection of Microbial DNA in Blood in Severe Infections Completed NCT00709358 Phase 4
26 Antifungal Use in Oncohematological Neutropenic Patients Completed NCT00386802 Phase 4 Antifungal drug. VORICONAZOL. (VFEND®)
27 The Tobramycin Study Completed NCT00257790 Phase 4 Tobramycin once a day
28 Steady-State Comparative Bioavailability Study in Prophylaxis Patients of Lozanoc® 50 mg With Sporanox® 100 mg Completed NCT02621905 Phase 4 Sporanox;Lozanoc
29 An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL) Completed NCT02782845 Phase 4 Chemotherapy;Immunochemotherapy;Pegfilgrastim
30 Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer Completed NCT00883675 Phase 4 Docetaxel-Carboplatin
31 Value of the LightCycler® SeptiFast Test MGRADE for the Pathogen Detection in Neutropenic Hematological Patients Completed NCT01114165 Phase 4
32 Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer Completed NCT02441894 Phase 4 CABAZITAXEL XRP6258;PEG-G-CSF;Prednisolone;Dexchlorpheniramine or Diphenhydramine;Ranitidine;Metoclopramide, Granisetron, or Ondansetron;Dexamethasone
33 Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115) Completed NCT00686543 Phase 4 Posaconazole
34 PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy Completed NCT02805218 Phase 4 PEG-rhG-CSF
35 PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy Completed NCT02805166 Phase 4 PEG-rhG-CSF
36 Safety of Orectalip® (Oxaliplatin) as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer Completed NCT02284529 Phase 4 Orectalip
37 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4 Doxorubicin
38 Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide Completed NCT02502864 Phase 4 Standard of Care: Docetaxel;Standard of Care: Cyclophosphamide
39 Efficacy of Itraconazole as Secondary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation or Chemotherapy With Prior Invasive Fungal Infection Completed NCT01198236 Phase 4 Itraconazole
40 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
41 Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT Completed NCT01232504 Phase 4 rhGM-CSF group;rhG-CSF+rhGM-CSF group;rhG-CSF group
42 The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Influenza (Acute Upper Respiratory Infection) Completed NCT02622659 Phase 4 Fuganlin Oral Liquid;Xiaoer Jiebiao Oral Liquid
43 SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia Completed NCT00487448 Phase 4 Fludarabine;Cytarabine;G-CSF;Idarubicin
44 Oral Zinc Therapy for the Prevention of Mucositis Completed NCT00449592 Phase 4 Zinc;Placebo
45 Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours Completed NCT00220168 Phase 4 Irinotecan, Capecitabine
46 Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A Completed NCT02328963 Phase 4 Everolimus;mycophenolic acid
47 VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel Completed NCT01684813 Phase 4 Prasugrel.;Clopidogrel
48 Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
49 A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) Completed NCT01585324 Phase 4 peginterferon alfa-2a [Pegasys];ribavirin [Copegus]
50 Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3 Completed NCT00056862 Phase 4 Peginterferon alfa-2a;Peginterferon alfa-2a;Ribavirin

Search NIH Clinical Center for Neutropenia

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Neutropenia cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: neutropenia

Genetic Tests for Neutropenia

Genetic tests related to Neutropenia:

# Genetic test Affiliating Genes
1 Neutropenia 30

Anatomical Context for Neutropenia

MalaCards organs/tissues related to Neutropenia:

42
Breast, Lung, Myeloid, Neutrophil, Bone, T Cells, Bone Marrow

Publications for Neutropenia

Articles related to Neutropenia:

(show top 50) (show all 4023)
# Title Authors Year
1
Doripenem versus meropenem as first-line empiric therapy of febrile neutropenia in patients with acute leukemia: a prospective, randomized study. ( 30824955 )
2019
2
Neutropenia During Tocilizumab Treatment Is Not Associated With Infection Risk in Systemic or Polyarticular-Course Juvenile Idiopathic Arthritis. ( 30824645 )
2019
3
Neutropenia in Barth syndrome: characteristics, risks, and management. ( 30451719 )
2019
4
Cost-effectiveness analysis of UGT1A1*6/*28 genotyping for preventing FOLFIRI-induced severe neutropenia in Chinese colorectal cancer patients. ( 30628534 )
2019
5
Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy. ( 30727980 )
2019
6
Neutropenia management in patients receiving myelosuppressive polychemotherapy for early breast cancer in Belgium: BRONS study results. ( 30609907 )
2019
7
First case of neutropenia and thrombocytopenia in the setting of cerebral cavernous malformation 3. ( 30904992 )
2019
8
Successful treatment of chromoblastomycosis using ALA-PDT in a patient with leukopenia. ( 30769166 )
2019
9
Efficacy of olorofim (F901318) against Aspergillus fumigatus, A. nidulans, and A. tanneri in murine models of profound neutropenia and chronic granulomatous disease. ( 30885903 )
2019
10
Trends in Incidence and Outcomes of Clostridium difficile Colitis in Hospitalized Patients of Febrile Neutropenia: A Nationwide Analysis. ( 30614941 )
2019
11
Serpin B1 defect and increased apoptosis of neutrophils in Cohen syndrome neutropenia. ( 30843084 )
2019
12
Juvenile ecthyma gangrenosum caused by Pseudomonas aeruginosa revealing an underlying neutropenia: case report and review of the literature. ( 30633375 )
2019
13
Failure to eliminate a phosphorylated glucose analog leads to neutropenia in patients with G6PT and G6PC3 deficiency. ( 30626647 )
2019
14
Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor. ( 30451720 )
2019
15
Profound Neutropenia with Concomitant Hepatitis During Oxacillin Therapy. ( 30868036 )
2019
16
Neutropenia, Hypoxia, and the Complexities of Emergency Medicine: A Case of Dapsone-Induced Methemoglobinemia. ( 30803846 )
2019
17
Severe Transitory Neonatal Neutropenia Associated with Maternal Autoimmune or Idiopathic Neutropenia. ( 30900095 )
2019
18
Comparison of neutropenia profiles in different treatment protocols for acute myeloid leukemia using the D-index. ( 30684252 )
2019
19
c-D-index is a risk factor for prolonged febrile neutropenia during chemotherapy in patients with acute myeloid leukemia. ( 30604157 )
2019
20
Genetic variation in the ATP binding cassette transporter ABCC10 is associated with neutropenia for docetaxel in Japanese lung cancer patients cohort. ( 30890141 )
2019
21
Novel multiple heterozygous NUDT15 variants cause an azathioprine-induced severe leukopenia in a patient with systemic lupus erythematosus. ( 30742971 )
2019
22
Chronic Neutropenia in Children With Abscess Forming Cervical Lymphadenitis Caused by Staphylococcus aureus. ( 29613972 )
2019
23
Meningitis in a patient with neutropenia due to Rothia mucilaginosa: a case report. ( 30857551 )
2019
24
Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis. ( 30635476 )
2019
25
Mutation, drift and selection in single-driver hematologic malignancy: Example of secondary myelodysplastic syndrome following treatment of inherited neutropenia. ( 30615612 )
2019
26
How we approach: Severe congenital neutropenia and myelofibrosis due to mutations in VPS45. ( 30294941 )
2019
27
Erratum to correct "How we approach: Severe congenital neutropenia and myelofibrosis due to mutations in VPS45". ( 30793510 )
2019
28
Predictors of rituximab-related neutropenia in Japanese children with steroid-dependent nephrotic syndrome. ( 30887110 )
2019
29
Response to "Predictors of rituximab-related neutropenia in Japanese children with steroid-dependent nephrotic syndrome". ( 30915547 )
2019
30
Reduction of CFU-GM and circulating hematopoietic progenitors in a subgroup of children with chronic neutropenia associated with severe infections and delayed recovery. ( 30870474 )
2019
31
The effect of neutropenia on the clinical pharmacokinetics of vancomycin in adults. ( 30877327 )
2019
32
Evaluation of pharmacokinetic/pharmacodynamic and clinical outcomes with 6-hourly empiric piperacillin-tazobactam dosing in hematological malignancy patients with febrile neutropenia. ( 30879981 )
2019
33
Ex vivo Manufactured Neutrophils for Treatment of Neutropenia-A Process Economic Evaluation. ( 30881955 )
2019
34
An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients CALGB 80303 (Alliance). ( 30889042 )
2019
35
Ultra-Sensitive CSF3R Deep Sequencing in Patients With Severe Congenital Neutropenia. ( 30891028 )
2019
36
Mannose binding lectin and prediction of risk for chemotherapy induced febrile neutropenia in patients with a solid tumor. ( 30907154 )
2019
37
Natural history of benign ethnic neutropenia in individuals of African ancestry. ( 30909074 )
2019
38
A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia. ( 30913226 )
2019
39
Outcomes of a clinical pathway for primary outpatient management of pediatric patients with low-risk febrile neutropenia. ( 30916887 )
2019
40
Continuing Clozapine Treatment in Acute Psychosis With Neutropenia. ( 30282512 )
2019
41
Mechanisms of leukemic transformation in congenital neutropenia. ( 30431463 )
2019
42
SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018). ( 30470991 )
2019
43
Neutropenia in the age of genetic testing: Advances and challenges. ( 30536760 )
2019
44
Prospective Evaluation of Multinational Association of Supportive Care in Cancer Risk Index Score for Gynecologic Oncology Patients With Febrile Neutropenia. ( 30557164 )
2019
45
Prognostic value of procalcitonin and lipopolysaccharide binding protein in cancer patients with chemotherapy-associated febrile neutropenia presenting to an emergency department. ( 30591812 )
2019
46
The Duffy antigen receptor for chemokines, ACKR1,- 'Jeanne DARC' of benign neutropenia. ( 30592023 )
2019
47
Risk factors for extended-spectrum beta-lactamase-producing Enterobacteriaceae infection causing septic shock in cancer patients with chemotherapy-induced febrile neutropenia. ( 30600529 )
2019
48
Image Gallery: Poikiloderma with neutropenia. ( 30604532 )
2019
49
Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer. ( 30605229 )
2019
50
Common misconceptions in the prognostic evaluation of clinically stable patients with febrile neutropenia and solid tumors. ( 30607791 )
2019

Variations for Neutropenia

ClinVar genetic disease variations for Neutropenia:

6 (show all 13)
# Gene Variation Type Significance SNP ID Assembly Location
1 VPS13B NM_017890.4(VPS13B): c.11314C> T (p.Gln3772Ter) single nucleotide variant Pathogenic rs386834061 GRCh37 Chromosome 8, 100880540: 100880540
2 VPS13B NM_017890.4(VPS13B): c.11314C> T (p.Gln3772Ter) single nucleotide variant Pathogenic rs386834061 GRCh38 Chromosome 8, 99868312: 99868312
3 SLC37A4 NM_001164277.1(SLC37A4): c.81T> A (p.Asn27Lys) single nucleotide variant Conflicting interpretations of pathogenicity rs193302889 GRCh37 Chromosome 11, 118899999: 118899999
4 SLC37A4 NM_001164277.1(SLC37A4): c.81T> A (p.Asn27Lys) single nucleotide variant Conflicting interpretations of pathogenicity rs193302889 GRCh38 Chromosome 11, 119029289: 119029289
5 46;XY;t(16;20)(q23.1;p11.22) Translocation Uncertain significance
6 46;XX;inv(2)(q13q14.2) inversion Uncertain significance
7 XDH NM_000379.3(XDH): c.3647C> A (p.Pro1216His) single nucleotide variant Uncertain significance rs143981573 GRCh38 Chromosome 2, 31339616: 31339616
8 XDH NM_000379.3(XDH): c.3647C> A (p.Pro1216His) single nucleotide variant Uncertain significance rs143981573 GRCh37 Chromosome 2, 31562482: 31562482
9 VPS13B NM_017890.4(VPS13B): c.4620delA (p.Ser1541Profs) deletion Pathogenic rs1057518939 GRCh37 Chromosome 8, 100523652: 100523652
10 VPS13B NM_017890.4(VPS13B): c.4620delA (p.Ser1541Profs) deletion Pathogenic rs1057518939 GRCh38 Chromosome 8, 99511424: 99511424
11 subset of 47 genes:TBX1 GRCh37/hg19 22q11.21(chr22: 18894835-21505417) copy number loss Pathogenic GRCh37 Chromosome 22, 18894835: 21505417
12 XDH NM_000379.4(XDH): c.1172C> T (p.Pro391Leu) single nucleotide variant Uncertain significance GRCh37 Chromosome 2, 31602803: 31602803
13 XDH NM_000379.4(XDH): c.1172C> T (p.Pro391Leu) single nucleotide variant Uncertain significance GRCh38 Chromosome 2, 31379937: 31379937

Expression for Neutropenia

Search GEO for disease gene expression data for Neutropenia.

Pathways for Neutropenia

GO Terms for Neutropenia

Biological processes related to Neutropenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.67 CSF2 CSF3 CSF3R IL3
2 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.5 CSF3 HAX1 IL3
3 drug metabolic process GO:0017144 9.43 TPMT UGT1A1
4 positive regulation of actin cytoskeleton reorganization GO:2000251 9.4 CSF3 HAX1
5 regulation of myeloid cell differentiation GO:0045637 9.26 CSF2 CSF3R
6 neutrophil migration GO:1990266 9.16 CD177 JAGN1
7 glucose-6-phosphate transport GO:0015760 8.96 G6PC3 SLC37A4
8 neutrophil differentiation GO:0030223 8.62 CSF2 JAGN1

Sources for Neutropenia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....